2026 Eastern States Conference

Authors: Tina Lin, PharmD; Eris Cani, BS, PharmD, BCIDP, BCPS; Lendelle Raymond, MS, PharmD, BCIDP, AAHIVP; Cosmina Zeana, MD, MPH; James Lin, PharmD; Kyoung-Sil Kang, PharmD, BCPS, BCOP; Momina Qureshi, PharmD  

Learning Objective: At the conclusion of my presentation, the participant will be able to describe the impact of a provider education on the rate of appropriate statin prescribing for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in people living with HIV (PLWH).

Background/Objective: People living with HIV have an increased risk of ASCVD. Despite guideline updates following the REPRIEVE trial, statins remain underutilized. This study evaluates whether provider education improves appropriate statin prescribing.  

Methods: This quasi-experimental pre–post pilot study used retrospective chart review of people living with HIV at an urban HIV clinic who are eligible for statin therapy per 2024 DHHS guidelines during pre- (January–August 2025) and post-intervention (November 2025–January 2026) periods. Patients aged 40–75 years were assessed for appropriate statin use based on guideline-recommended indications and statin intensity. The intervention included provider education through in-service sessions that reviewed guideline recommendations and key trial data. The primary outcome was the proportion of patients prescribed appropriate statin therapy pre- versus post-intervention. The secondary outcome was adherence to guideline recommendations stratified by the ASCVD risk category. The statistical analysis included descriptive statistics to summarize baseline characteristics and a Chi-square test for categorical data. A p-value of < 0.05 was considered statistically significant.  

Results: A total of 92 patients were included (44 in the pre-intervention group and 48 in the post-intervention group). The proportion of patients receiving appropriate statin therapy increased from 36.4% in the pre-intervention group to 60.4% in the post-intervention group (p= 0.021). When stratified by ASCVD risk category, the intermediate-risk group accounted for the majority of guideline-adherence statin prescribing in both the pre- and post-intervention periods (68.7% and 48.3%, respectively). Notably, statin therapy was initiated among patients in the low ASCVD risk group during the post-intervention period (24%).

Conclusion: The proportion of patients prescribed appropriate statin therapy improved following provider education. These findings support the use of provider education to enhance guideline adherence.  

Self Assessment Question: A 52-year-old Hispanic male with well-controlled HIV on ART presents for routine follow-up. LDL is 78 mg/dL. His estimated 10-year ASCVD risk is 6%. Based on the 2024 DHHS HIV guidelines, should this patient be started on statin therapy?  

A. Yes, statin therapy is indicated
B. No, statin therapy is not indicated